Company Profile
Gemini Therapeutics
Company Overview
Gemini Therapeutics is a publicly traded biotechnology company pioneering precision therapeutics for patients with high-risk genetic profiles linked to dry age-related macular degeneration (AMD) and rare systemic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and Gemini’s broad multimodal pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, Gemini is developing a series of first-in-class therapeutics. The company currently has 30 employees and is growing quickly. More information is available at www.geminitherapeutics.com.